Trials and PIs

View all posts »

DEFINE with Dr Christopher Cannon

Nov 17, 2010 13:05 EST


Dr Christopher Cannon (TIMI Study Group, Boston MA) discusses primary results of the DEFINE: Determining the Efficacy and Tolerability of CETP Inhibition with Anacetrapib with Dr Gabriel Steg.

Filmed during AHA 2010 in Chicago, IL on November 14.

See:
DEFINE: Large effects on LDL and HDL cholesterol with CETP inhibitor anacetrapib





« Previous Post
Symplicity HTN-2 with Dr Murray Esler
Nov 17, 2010 13:10 EST Next post »
ACT Trial with Dr Otavio Berwanger
Nov 16, 2010 18:32 EST



Your comments
DEFINE with Dr Christopher Cannon
# 1 of 10
November 18, 2010 10:15 (EST)
kewal mahajan
finally hdl can be raised safely. i hope it changes outcomes as well.
# 2 of 10
November 25, 2010 12:52 (EST)
Canio Casale
It seems to be a very interesting drug.Waiting for a big trial
# 3 of 10
February 26, 2011 06:08 (EST)
Guillermo Varona
It is a very dramatic result which will redefine my management of hyperlipidemia.
# 4 of 10
February 26, 2011 07:43 (EST)
Guillermo Varona
information will dramaticaly improve patient lipid disorder management
# 5 of 10
February 26, 2011 07:44 (EST)
Guillermo Varona
information will dramaticaly improve patient lipid disorder management
# 6 of 10
February 26, 2011 07:48 (EST)
Guillermo Varona
Use of anatrecipab is very treatment in patient with low HDL and elevated LDL which I hope to use as soon as available.
# 7 of 10
February 26, 2011 07:49 (EST)
Guillermo Varona
Use of anatrecipab is very treatment in patient with low HDL and elevated LDL which I hope to use as soon as available.
# 8 of 10
February 26, 2011 07:52 (EST)
Guillermo Varona
Use of anatrecipab is very treatment in patient with low HDL and elevated LDL which I hope to use as soon as available.
# 9 of 10
February 26, 2011 07:52 (EST)
Guillermo Varona
Use of anatrecipab is very treatment in patient with low HDL and elevated LDL which I hope to use as soon as available.
# 10 of 10
February 26, 2011 07:53 (EST)
Guillermo Varona
Use of anatrecipab is very treatment in patient with low HDL and elevated LDL which I hope to use as soon as available. This is my final comment, thank you for a very educational presentation.

You must be a member (with full membership) to post a comment.
Already a member?
Enter your login information below:
 Remember me on this computer
Forgot your username and/or password?
        Login        
Enjoy all the benefits of theheart.org

With full membership, you can check out our educational and editorial content, search the site, receive our newsletters, join discussions, download slides and much more.

Membership is free!

    Join now for full access